Ken Griffin’s Silence Therapeutics SLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.9M Buy
2,825,601
+1,495,976
+113% +$18.2M ﹤0.01% 2070
2026
Q2
$14.6M Buy
1,329,625
+94,818
+8% +$667K ﹤0.01% 3011
2026
Q1
$6.51M Buy
1,234,807
+990,746
+406% +$5.45M ﹤0.01% 3919
2025
Q4
$1.48M Buy
244,061
+222,556
+1,035% +$1.42M ﹤0.01% 6536
2025
Q3
$112K Buy
+21,505
New +$119K ﹤0.01% 11766
2025
Q2
– Sell
-62,441
Closed -$176K – 14852
2025
Q1
$176K Sell
62,441
-220,296
-78% -$1.08M ﹤0.01% 10633
2024
Q4
$1.95M Sell
282,737
-153,960
-35% -$1.99M ﹤0.01% 5688
2024
Q3
$7.94M Buy
436,697
+319,937
+274% +$5.95M ﹤0.01% 3257
2024
Q2
$2.22M Buy
116,760
+74,078
+174% +$1.58M ﹤0.01% 5121
2024
Q1
$922K Buy
42,682
+20,945
+96% +$455K ﹤0.01% 7086
2023
Q4
$378K Buy
+21,737
New +$244K ﹤0.01% 8688
2022
Q4
– Sell
-22,851
Closed -$226K – 15407
2022
Q3
$226K Buy
22,851
+11,410
+100% +$120K ﹤0.01% 10157
2022
Q2
$136K Buy
+11,441
New +$139K ﹤0.01% 11079

Other funds holding SLN

Ken Griffin's SLN Position: Q3 2026 in Review

Ken Griffin increased its Silence Therapeutics (SLN) stake by 113% in Q3 2026, buying an estimated $18.2M and bringing the position to 2,825,601 shares worth $30.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Ken Griffin first reported a position in SLN in Q2 2022 and has held it in 13 quarters since. 92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Ken Griffin held 2,825,601 shares of Silence Therapeutics worth $30.9M as of Q3 2026.
  • Ken Griffin bought 1,495,976 Silence Therapeutics shares in Q3 2026, an estimated $18.2M.
  • Silence Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q3 2026, its #2070 holding.
  • Ken Griffin first reported a position in Silence Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.